Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

REMS And Benefits? FDA, Industry Debate Moving Beyond Safety Information

Executive Summary

Included in FDA's upcoming look at improving Risk Evaluation and Mitigation Strategies may be an adjustment to Medication Guides to include drug benefits alongside risks

You may also be interested in...



FDA “Reminds” Doctors To Talk About Drug Benefits

Proposed pilot program would look for the best patient counseling practices, but can FDA remind providers to discuss a drug’s benefits without actually specifying them?

One-Page MedGuide For Long-acting Opioids Sets Stage For Retooling MedGuide Format

The single-page format could serve as a template as FDA tries to simplify patient information that accompanies prescription drugs.

FDA's Long-Term Vision For REMS Includes "Plug-And-Play" Standardization

OND Director Jenkins notes that risk management plans should be interoperable, but will not be identical.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS052488

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel